Clindamycin Phosphate Gel USP, 1% For External Use

Manufacturer
Alembic Pharmaceuticals Inc. | Alembic Pharmaceuticals Limited
Effective date
2025-12-02
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
5
Source
daily-update
Hydrated at
2026-07-25 05:11:00

Label at a glance#

ProductCLINDAMYCIN PHOSPHATE
Active ingredientCLINDAMYCIN PHOSPHATE
Label structure11 sections

Indications and uses

Clindamycin phosphate gel is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS ).

Dosage and administration

Apply a thin film of clindamycin phosphate gel twice daily to affected area.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Clindamycin phosphate gel USP contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per gram.

Clindamycin phosphate is a water soluble ester of the semi-synthetic antibacterial drug produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.

The gel contains allantoin, carbopol 974P, methylparaben, polyethylene glycol 400, propylene glycol, sodium hydroxide, and purified water.

The structural formula is represented below:

structure
structure

The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate).

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Mechanism of Action

The mechanism of action of clindamycin in treating acne vulgaris is unknown.

Pharmacokinetics

Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0 to 3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin.

Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.

Microbiology

Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.

Antimicrobial Activity

Clindamycin is active in vitro against most isolates of Propionibacterium acnes; however, the clinical significance is unknown.

Resistance

Resistance to clindamycin is most often caused by modification of specific bases of the 23S ribosomal RNA. Cross-resistance between clindamycin and lincomycin is complete. Because the binding sites for these antibacterial drugs overlap, cross-resistance is sometimes observed among lincosamides, macrolides and streptogramin B. Macrolide-inducible resistance to clindamycin occurs in some isolates of macrolide-resistant bacteria.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Clindamycin phosphate gel is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see CONTRAINDICATIONS, WARNINGS and ADVERSE REACTIONS).

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Clindamycin phosphate gel is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

WARNINGS

WARNINGS SECTION

Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in systemic absorption from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis. Stool culture for Clostridioides difficile and stool assay for C. difficile toxin may be helpful diagnostically. 

When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.

Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by Clostridioides difficile. The usual adult dosage is 500 milligrams to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days. Cholestyramine or colestipol resins bind vancomycin in vitro . If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.

Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.

PRECAUTIONS

PRECAUTIONS SECTION

General

Clindamycin phosphate gel should be prescribed with caution in atopic individuals.

Drug Interactions

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

Pregnancy: Teratogenic Effects

In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of congenital abnormalities. There are no adequate studies in pregnant women during the first trimester of pregnancy. Clindamycin should be used during the first trimester of pregnancy only if clearly needed.

Nursing Mothers

It is not known whether clindamycin is excreted in breast milk following use of clindamycin phosphate gel. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora. Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breast-fed child from clindamycin or from the underlying maternal condition.

Clinical Considerations 

If used during lactation and clindamycin phosphate gel is applied to the chest, care should be taken to avoid accidental ingestion by the infant.

Pediatric Use

Safety and effectiveness in pediatric patients under the age of 12 have not been established.

Geriatric Use

Clinical studies for clindamycin phosphate gel did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

In 18 clinical studies of various formulations of clindamycin phosphate solution, gel and lotion using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].

Number of Patients Reporting Events
Note
# not recorded
Note
*of 126 subjects
Treatment
Emergent
Adverse Event
Solution
n=553(%)

Gel
n=148(%)

Lotion
n=160(%)
Burning
62 (11)
15 (10)
17 (11)
Itching
36 (7)
15 (10)
17 (11)
Burning/Itching
60 (11)
# ( – )
# ( – )
Dryness
105 (19)
34 (23)
29 (18)
Erythema
86 (16)
10 (7)
22 (14)
Oiliness/Oily Skin
8 (1)
26 (18)
12* (10)
Peeling
61 (11)
# ( – )
11 (7)

Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.

Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS).

Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin.

OVERDOSAGE

OVERDOSAGE SECTION

Topically applied clindamycin phosphate gel can be absorbed in sufficient amounts to produce systemic effects (see WARNINGS).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Apply a thin film of clindamycin phosphate gel twice daily to affected area.

HOW SUPPLIED

HOW SUPPLIED SECTION

Clindamycin phosphate gel USP, 1% is clear, colorless gel containing clindamycin phosphate equivalent to 10 mg clindamycin per gram is available in the following sizes:

30 gram tube—NDC 62332-623-30

60 gram tube—NDC 62332-623-60

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Protect from freezing.

Preserve in tight containers.

Rx only

Manufactured for:

Alembic Pharmaceuticals, Inc.

Bedminster, NJ 07921, USA

Manufactured by:

Alembic Pharmaceuticals Limited

(Derma Division),

Karakhadi, Vadodara 391450, India.

Mfg. License No.: G/28/1626

Revised: 12/2025

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

30 gram Tube label

NDC 62332-623-30

30 grams

Rx only

Clindamycin Phosphate Gel USP, 1%*

tube label
tube label

30 gram Carton label

NDC 62332-623-30

30 grams

Rx only

Clindamycin Phosphate Gel USP, 1%*

carton label
carton label

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130362332623303GTIN-13: 0362332623303
EAN-13: 0362332623303
GTIN-12: 362332623303
UPC-A: 362332623303
GTIN storage (14 digits): 00362332623303
cd70c834-02ff-4efc-9f47-f3afc7bce65f-02.jpg, cd70c834-02ff-4efc-9f47-f3afc7bce65f-03.jpg
Data codeData Matrix(01)A890382100000X(17)171200(10)1234567890cd70c834-02ff-4efc-9f47-f3afc7bce65f-03.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
a46239a7-5963-4008-8cbb-6b9000f497ebProduct name120250721
1426d8f8-b7d5-4053-8554-613df00c0d86Product name220250616
b382b4e1-6b48-45f6-bffc-e61b00b0ce19Product name320250317
d8f81258-db12-0761-46cc-8ff6e62e9302Product name420240422
b7b2fa42-1c77-d724-81f0-87da60a77e79Product name320240320
b27c7c65-51f2-a62f-e0e6-a26b3a0f8eb0Product name320230425
e3af9708-3004-7392-4046-5311eaa8bab5Product name320221128
ffb4bacf-f636-0f7d-0b0d-7a4b151243e3Product name920220928
b72227d6-0388-43bd-995b-b762d2754cd5Product name120220706
a92d22e0-3af4-f301-bc88-27ff030b0070Product name220220316
4a7d44fe-774d-404b-aad0-8a90fe78375aProduct name420211025
d12e2d7c-bd6b-45d4-94f9-6df8e1b8b27bProduct name320200203
ee5c6de5-d9cd-454f-b250-7b19e5cf2992Product name420190619
5ce6ce33-4f2b-3ce0-757d-e520013280cfProduct name520180719
b92a26f1-6926-4817-be73-e26ab4c2146fProduct name120170602
028d6c95-5012-6976-2075-dee0ae6fefe2Product name120140508
468b2c08-8adb-8d0f-8257-c6515a061424Product name120140508
8959fb29-d86f-c521-666a-b4cb22233594Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
62332-623-30GM - Gram62332-6232ddcf590-fe63-4cb9-9aaf-d7e7d763375912024-05-16
62332-623-60GM - Gram62332-62341eb57ff-5f20-4a59-99e6-7757ab36b79412024-06-10

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
62332-62362332-623-60, 62332-623-30

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
42024-04-04full-release2026-05-31 21:01:35

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A212466-001CLINDAMYCIN PHOSPHATECLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-02

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A212466-001AB1

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-02d4dbc9d85df4…
2026-10-15 13:18:302026-09A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-02c2088c7a36db…
2026-09-14 22:38:342026-08A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-0284e616aacf4f…
2026-08-18 06:07:402026-07A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-02caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-02011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-0231067a03dcf5…
2025-08-23 18:47 UTC2025-08A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-026a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-02fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-02b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-0203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-022680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-025bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-02d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-02d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-0279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-02301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-021e350fbaab3a…
2024-05-31 18:47 UTC2024-05A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-028072bd15b7f6…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A212466-001CLINDAMYCIN PHOSPHATEEQ 1% BASEGEL / TOPICALAB12024-04-02a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A212466-001AB11d4dbc9d85df4…
2026-10-15 13:18:302026-09A212466-001AB11c2088c7a36db…
2026-09-14 22:38:342026-08A212466-001AB1184e616aacf4f…
2026-08-18 06:07:402026-07A212466-001AB11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A212466-001AB11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A212466-001AB1131067a03dcf5…
2025-08-23 18:47 UTC2025-08A212466-001AB116a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A212466-001AB11fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A212466-001AB11b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A212466-001AB1103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A212466-001AB112680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A212466-001AB115bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A212466-001AB11d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A212466-001AB11d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A212466-001AB1179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A212466-001AB11301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A212466-001AB111e350fbaab3a…
2024-05-31 18:47 UTC2024-05A212466-001AB118072bd15b7f6…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A212466-001AB11a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CLINDAMYCIN PHOSPHATECLINDAMYCIN PHOSPHATEAlembic Pharmaceuticals Inc.96434354-a646-4869-92a2-4052d3f7a4aa2025-12-02Warnings, Adverse reactionsExact identifier
ndc (package): 62332-623-30
ndc (package): 62332-623-60
ndc (product): 62332-623
ndc11 (package): 62332062360
ndc11 (package): 62332062330
spl id: 61470c35-bf23-4873-ac7e-e98af53926be
spl set id: 96434354-a646-4869-92a2-4052d3f7a4aa

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.